Comparative Pharmacology
Head-to-head clinical analysis: FILSPARI versus IRBESARTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FILSPARI versus IRBESARTAN.
FILSPARI vs IRBESARTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FILSPARI (sparsentan) is an endothelin receptor antagonist (ERA) and angiotensin II receptor blocker (ARB) with high affinity for the endothelin type A (ETA) receptor and angiotensin II type 1 (AT1) receptor. It reduces proteinuria in IgA nephropathy by inhibiting endothelin-1 mediated vasoconstriction, inflammation, and fibrosis, and by blocking angiotensin II mediated effects.
Irbesartan is an angiotensin II receptor blocker (ARB) that selectively and competitively inhibits the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, thereby blocking vasoconstriction and aldosterone secretion.
200 mg orally once daily, with or without food.
150 mg orally once daily; may increase to 300 mg once daily if needed.
None Documented
None Documented
Clinical Note
moderateIrbesartan + Benzydamine
"The risk or severity of adverse effects can be increased when Irbesartan is combined with Benzydamine."
Clinical Note
moderateIrbesartan + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Irbesartan."
Clinical Note
moderateIrbesartan + Droxicam
"The risk or severity of adverse effects can be increased when Irbesartan is combined with Droxicam."
Clinical Note
moderateIrbesartan + Loxoprofen
Terminal half-life ~30 hours in healthy subjects, supporting once-daily dosing.
The terminal elimination half-life of irbesartan is 11–15 hours, supporting once-daily dosing.
Primarily hepatic metabolism; <1% excreted unchanged in urine. ~59% of dose recovered in feces and ~27% in urine as metabolites.
Irbesartan is primarily eliminated via biliary/fecal excretion (approximately 80%) and renal excretion (approximately 20%).
Category C
Category D/X
Endothelin Receptor Antagonist / ARB
ARB
"The risk or severity of adverse effects can be increased when Irbesartan is combined with Loxoprofen."